Drug Profile
AG 6840
Latest Information Update: 21 Sep 2006
Price :
$50
*
At a glance
- Originator Agouron Pharmaceuticals
- Class Antivirals
- Mechanism of Action Rhinovirus 3C protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Common cold
Most Recent Events
- 21 Sep 2006 Discontinued - Preclinical for Rhinovirus infections in USA (unspecified route)
- 20 Jul 2000 Profile reviewed but no significant changes made
- 22 Jun 2000 Warner-Lambert has merged with Pfizer